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Neuroblastoma, the most common extracranial solid tumour of childhood, is a malignancy of un-
known origin and non-specific symptoms. One of the markers of the disease is GD2 ganglio-
side (disialoganglioside), which is abundantly expressed on the surface of neuroblastoma cells. 
Gangliosides are known to be shed by tumour cells and this phenomenon can be significant in 
cancer progression as they inhibit a number of immune responses both in vitro and in vivo. In 
search for novel markers useful in monitoring and prognosis of neuroblastoma, we developed 
and validated a new quantitative method of GD2 ganglioside analysis in human blood plasma. 
We evaluated the level of gangliosides in blood serum of 34 neuroblastoma patients using high-
performance liquid chromatography. The technique was used to detect fluorescently labelled 
oligosaccharides derived from serum glycosphingolipids by enzymatic digestion with ceramide 
glycanase. The developed method allowed determination of GD2 concentrations at the picomole 
level and required only 40 μl of plasma, which should be particularly useful when the quantity 
of clinical material is limiting. Moreover, this method can be applied to study concentration of 
other gangliosides, as shown for GD3 ganglioside. Analysis of plasma samples from the 34 neu-
roblastoma patients did not reveal any correlations between the concentration of GD2 ganglio-
side and clinical parameters, including the results of therapy; it showed, however, that the con-
centration of GD2 ganglioside in the plasma of neuroblastoma patients decreased substantially 
in the course of treatment.
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InTrODucTIOn
Neuroblastoma (NB) is a paediatric neoplasm 
that occurs mostly in children less than 5 years old. 
The disease develops from precursor cells of the pe-
ripheral nervous system and the primary tumour 
is usually located in adrenal glands, but may also 
occur in other sympathetic neuron sites. NB is the 
most common extracranial solid tumour of child-
hood, with 6–11 new cases each year per million 
children aged 0–15 years. In Poland, about 60 new 
cases of NB are diagnosed annually (Balwierz, 2004). 
Aetiology of the disease remains unknown. At diag-
nosis, the disease is usually spread to metastatic foci, 
Corresponding author: Hanna Rokita, Laboratory of Molecular Genetics and Virology, Faculty of Biochemistry, Biophys-
ics and Biotechnology, Jagiellonian University, ul. Gronostajowa 7, 30-387 Kraków, Poland; phone: (48) 12 664 6337; fax: 
(48) 12 664 6902; e-mail: hanna.rokita@uj.edu.pl
*Presented at the XXXVI Winter School “Molecule interactions in health and disease” organized by the Faculty of Bio-
chemistry, Biophysics and Biotechnology, Jagiellonian University, 21–26 February, 2009, Zakopane, Poland.
Abbreviations: FBS, fetal bovine serum; FITC, fluorescein isothiocyanate; GU, glucose units; HPLC, high performance 
liquid chromatography; LDH, lactate dehydrogenase; MFI, mean fluorescence intensity; NB, neuroblastoma; NSE, neuro-
specific enolase; PBS, phosphate-buffered saline.
Vol. 56 No. 3/2009, 423–431
on-line at: www.actabp.pl
424            2009D. Czaplicki and others
primarily in the lymph nodes and bone marrow and 
bones. Nevertheless, NB has the highest rate of spon-
taneous remission among all human tumours. NB in 
infants may occur with a specific pattern of metas-
tases to liver and skin, but in spite of this the dis-
ease has favourable prognosis and usually responds 
well to chemotherapy or spontaneously undergoes 
complete remission (Evans et al., 1981). In contrast, 
the prognosis of metastatic disease in children over 
1 year old is bad. The current treatment protocols of 
NB are based on chemotherapy combined with sur-
gical removal of the tumour. Irradiation is used as 
a complementary therapy. In cases with bad prog-
nosis, megachemotherapy followed by autologous 
bone marrow transplant is used to destroy residual 
cancer cells. Despite intensive treatment, the long-
term survival in advanced NB is as low as 30% (Bal-
wierz, 2004). The major challenge is the treatment of 
minimal residual disease associated with incomplete 
removal of tumour cells by chemo- and radiotherapy 
(Beiske et al., 2005). New therapeutic options are un-
der development, including: passive immunothera-
py, radioimmunotherapy, tyrosine kinase inhibitors 
and anti-angiogenic therapies (Brodeur, 2003).
Prognostic factors in nB. The clinical course 
of NB can be very heterogeneous and a number of 
factors have been found relevant for prognosis and 
monitoring of the disease. Two most important fac-
tors are: patient’s age at diagnosis and stage of the 
disease. The biological features of NB in infants are 
different than in older children (>1 y.o.). In most in-
fants the metastatic form of the disease can be suc-
cessfully treated with limited chemotherapy or solely 
with surgical procedure, while patients more than 1 
year old require a much more aggressive treatment. 
Depending on the advancement of the disease, NB 
is staged from 1 to 4 according to the International 
Neuroblastoma Staging System. In some cases, par-
ticularly in infants, the tumour undergoes spontane-
ous remission (NB stage 4S), while in older children 
it may differentiate to a benign form of ganglioneu-
roma. Histology of the tumour is also of prognostic 
significance; in NB two histological types have been 
defined: favourable and unfavourable, depending 
on the degree of differentiation and the mitotic in-
dex (Shimada et al., 1999). Serum levels of three bio-
chemical markers — ferritin, lactate dehydrogenase 
(LDH) and neurospecific enolase (NSE) — seem to 
be significant in NB; elevated concentrations of those 
markers are associated with worse prognosis (Riley 
et al., 2004). Several genetic markers are important 
prognostic factors in NB; those include MYCN on-
cogene amplification, genome ploidy and chromo-
somal aberrations in the tumour cells (Weinstein et 
al., 2003).
Gangliosides of malignant cells. Ganglio-
sides are a class of complex molecules belonging to 
glycosphingolipids. Their structure is formed by the 
ceramide core and a sugar chain of several carbo-
hydrate residues, including at least one sialic acid. 
Ganglioside biosynthesis is a complex enzymatic 
pathway (d’Azzo et al., 2006). Gangliosides are com-
ponents of eukaryotic cell membranes — mainly in 
the central nervous system, but are also found on 
the surface of cancer cells. However, ganglioside ex-
pression in malignant cells is often altered. For ex-
ample, the number and linkage of sialic acids can 
change, leading to production of atypical glycolipid 
molecules (Varki, 1999). Moreover, in many cancers 
such as melanoma, soft tissue sarcoma and small 
cell lung cancer the pathway of ganglioside synthe-
sis is shortened, which is manifested by overexpres-
sion of simpler forms such as GM3, GD3, GM2 and 
GD2 (Hettmer et al., 2003; nomenclature according 
to Svennerholm, 1980). This phenomenon is related 
to neoplastic transformation, e.g., GD3 ganglioside is 
abundant on melanoma cells, but only small quanti-
ties are present on normal melanocytes (Carubia et 
al., 1984). Ganglioside overexpression may occur in 
more than 90% of cases of a particular type of cancer 
(Chang et al., 1992). Differentiation of tumour cells 
induced in vitro leads to the restoration of a normal 
expression profile of gangliosides (Liour et al., 2000).
Surface gangliosides can be shed from the 
cell membranes in a number of ways — ganglio-
sides may be released in the form of micelles and 
aggregates (Kong et al., 1998) as well as complexes 
with antibodies (Hakansson et al., 1985) and plas-
ma proteins (Valentino & Ladisch, 1992). Ganglio-
side shedding seems to have biological importance 
— there are reports that the circulating gangliosides 
are able to weaken cellular immunity and thereby 
accelerate tumour progression (Sietsma et al., 1998). 
Several mechanisms of immunosuppression are pos-
sible: loss of antigen from the surface of cancer cells, 
blocking of specific antibodies and T cell receptors or 
direct suppression of patient’s lymphocytes (Ladisch 
et al., 1994). Some gangliosides may also inhibit the 
biological activity of cytokines, such as interleukin 2 
(Ravindranath et al., 2001).
GD2 ganglioside in neuroblastoma. GD2 gan-
glioside (disialoganglioside) is one of the antigens as-
sociated with NB. Chemically, GD2 is a derivative of 
cerebroside containing two sialic acid residues; the 
structure of GD2 is: GalNAcβ1 → 4 (Neu5Acα2 → 
8) (Neu5Acα2 → 3) Galβ1 → 4Glcβ1 → 1’-ceramide 
(Fig. 1). The antigen is characteristic to cells of neur-
oectodermal origin and its normal distribution in the 
human organism is limited to neurons and peripher-
al nerve fibres (Varki, 1999). The GD2 content on NB 
cells is particularly high and may reach up to 30% 
of all gangliosides present on the cell surface (Wu et 
al., 1986). In addition, the antigen is shed from the 
tumour cell and released into the bloodstream (Li 
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& Ladisch, 1991), and its concentration in the blood 
may be correlated with progression of the disease 
(Ladisch et al., 1987). It has been suggested that the 
increased shedding of GD2 ganglioside and MYCN 
amplification jointly characterise the aggressive type 
of NB cells (Valentino et al., 1990).
MATerIAls AnD MeThODs
cell lines. A hybridoma cell line producing 
14G2a murine monoclonal antibody specific to GD2 
ganglioside (Mujoo et al., 1989) was a kind gift from 
Dr. R. A. Reisfeld from the Scripps Institute (La 
Jolla, CA, USA). HTLA-230 cell line was a kind gift 
from Professor Vito Pistoia from the Gaslini Institute 
(Genova, Italy). IMR-32, BE(2)-C, SH-SY5Y and SK-
MEL-28 cell lines were obtained from ATCC.
clinical samples. A total of 42 blood serum 
samples from 34 patients diagnosed with differ-
ent stages of NB were collected between 2003 and 
2008 at the Department of Paediatric Oncology and 
Haematology of the University Children’s Hospital 
(Kraków, Poland). In six cases, two different sam-
ples were obtained from the same patient, and in 
one case — three samples from the same patient. 
Where possible, the samples were collected before 
treatment, after treatment and at a follow-up time 
point (14–33 months after treatment). Samples were 
also collected from seven patients with non-neurob-
lastoma disease; those samples were used as con-
trols in HPLC analysis (non-NB). Collection of clini-
cal samples was authorised by the Bioethical Com-
mission of the Jagiellonian University (opinion no. 
KBET/311/B/2002, prolonged accordingly).
characteristics of patients. Clinical parame-
ters were gathered on the basis of available medical 
records. In the group of 34 patients, 17 were male 
(50%) and 17 female (50%). Age of patients at the 
time of diagnosis ranged from 39 days to 12 years, 
median 22.3 months. Twelve (35.3%) and 22 (64.7%) 
patients were in the age group below 1 year of 
age and above 1 year of age, respectively. NB was 
staged in all patients according to the International 
Neuroblastoma Staging System: the largest group 
— 19 (55.9%) patients — were patients with stage 4 
NB; 1 (2.9%), 5 (14.7%) and 7 (20.6%) patients were 
diagnosed in stages 1, 2 and 3, respectively; 2 (5.9%) 
patients had NB stage 4S. MYCN gene amplifica-
tion was observed in 4 (11.8%) patients, for another 
4 (11.8%) MYCN analysis results were not available 
and in the remaining 26 patients (76.4%) normal 
copy number of MYCN was found. The histological 
type of the tumour, assessed according to the In-
ternational Neuroblastoma Pathology Classification 
criteria, was found to be favourable in 13 (38.2%) 
patients and unfavourable in 14 (41.2%) patients; 
in other cases, histopathological evaluation was not 
possible. The patients exhibited high variability of 
biochemical parameters: the level of LDH in plas-
ma varied in the range 393–5 966 IU/l (mean 2 049.4 
IU/l), while NSE levels in plasma ranged from 0 to 
1 122.8 ng/ml, with an average value of 200.7 ng/ml. 
All patients with NB were treated according to the 
current European SIOPEN protocols with the follow-
ing results: 29 patients survived (24 with no disease 
progression, 5 after progression or in relapse, in two 
cases — early stage treatment), 5 patients died (4 as 
a result of progression, 1 due to complications).
Isolation of blood plasma. Plasma was iso-
lated by centrifugation in density gradient. Blood 
(5 ml) was layered on 5 ml of Ficoll (density 1.077 
g/cm3) in a 15-ml tube. The tube was then centri-
fuged for 30 min at 800 × g at room temperature. Af-
ter separation the plasma was collected as the upper 
phase.
lipid extraction and isolation of ganglio-
sides. Plasma samples (40 μl) or cell pellets (5 × 105) 
were extracted with 4 ml of a mixture of chloro-
form/methanol, 2:1 (v/v) and shaken vigorously for 
15 s in a glass tube. The solution was sonicated for 
15 min in an ultrasonic water bath at 22°C and then 
incubated on ice for 2 min. The samples were centri-
fuged for 10 min at 4°C and 3 200 × g. The superna-
tant was transferred to a clean tube and dried under 
a stream of nitrogen. Then, after dissolving in 200 
μl of chloroform, the obtained mixture of lipids was 
applied to a column containing 0.1 g silicic acid in 
1 ml of chloroform. Specific lipid fractions were se-
quentially eluted from the column with 5 ml of chlo-
roform (neutral lipids), 1.8 ml of methanol/acetone 
mixture, 1 : 9 (v/v; neutral glycolipids) and 1.8 ml of 
methanol (gangliosides). The last fraction, containing 
gangliosides, was dried in a vacuum concentrator 
and then dissolved in 10 μl of buffer for enzyme di-
Figure 1. schematic chemical structure of GD2 ganglio-
side.
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gestion, which consisted of 1 mg/ml sodium cholate 
dissolved in 50 mM sodium acetate, pH 5.0.
enzymatic digestion of gangliosides. After 
complete dissolution of the sample, 10 μl of cera-
mide glycanase solution (Merck Biosciences) was 
added at a concentration of 5 U/ml, which gave the 
final activity of 0.05 U per sample. The enzymatic 
reaction lasted for 18 h and was conducted at 37°C.
Glycan purification. After completion of di-
gestion, the glycans in the reaction mixture were 
separated from the ceramide, enzyme and other 
contaminants by column purification using an Oa-
sis HLB 10 mg cartridge (Waters). The column resin 
was activated beforehand with 1 ml of methanol 
and equilibrated with 1 ml of HPLC grade water; 
180 μl of HPLC grade water was added to the reac-
tion mixture and the entire solution was transferred 
to the Oasis column. The reaction tube was washed 
with 50 μl of water which was then transferred to 
the column. The column was washed with 200 μl 
of 5% (v/v) methanol in HPLC grade water and the 
combined eluate was dried in a vacuum concentra-
tor.
Fluorescent labelling of glycans. The puri-
fied glycan samples were labelled with 2-aminoben-
zamide using the GlycoProfile 2-AB Labeling Kit 
(Sigma-Aldrich) according to the manufacturer’s in-
structions.
high performance liquid chromatography. 
Labelled glycan samples were diluted by adding 
200 μl of HPLC grade water. A Shimadzu model 
10AVP HPLC system was used for chromatog-
raphy, equipped with a 105 × 4.6 mm Hypersil 
ODS(C18) 3 μm column (Phenomenex, Cat. No. 
00F-0145-E0). Reversed-phase HPLC was per-
formed in a two-phase system in which phase A 
was 50 mM formic acid brought to pH 5.0 with 
triethylamine, while phase B consisted of a 1 : 1 
mixture of phase A and HPLC grade acetonitrile. 
The injection volume for each sample was 180 μl. 
A gradient with the following time programme 
was used: t = 0 min, flow 0.5 ml/min, 95% phase 
A; t = 30 min, 0.5 ml/min, 95% phase A; t = 95 
min, 0.5 ml/min, 90% phase A; t = 100 min, 0.5 
ml/min, 76% phase A; t = 101 min, 1.5 ml/min, 
5% phase A; t = 107 min, 1.5 ml/min, 5% phase 
A; t = 108 min, 1.5 ml/min, 95% phase A; t = 112 
min, 1.5 ml/min, 95% phase A; t = 113 min, 0.5 ml/
min, 95% phase A; total time: 114 min. Following 
column separation, the labelled glycans were de-
tected using a Shimadzu RF-10AXL fluorescence 
detector with excitation wavelength of 330 nm 
and the emitted signal was measured at 420 nm. 
Chromatograms were recorded and analyzed us-
ing Shimadzu Class VP software ver. 6.
Qualitative analysis of hPlc data. Qualita-
tive analysis was based on a comparison of the re-
tention times of detected components with the re-
tention times of standards, which were glycans iso-
lated from commercially available gangliosides GM1, 
GM3, GD2, GD3 (Merck Biosciences) and a mixture 
of gangliosides from bovine brain (Sigma-Aldrich). 
In order to confirm the validity of the method, the 
retention times obtained for the standards were 
compared with previously published values (Wing 
et al., 2001). Due to the differences in methodology, 
the retention time was converted into glucose units 
(GU). Fluorescently labelled samples of arabinobiose 
(Megazyme) with GU = 2 and arabinotriose (Meg-
azyme) with GU = 3 were used as reference samples. 
The values compared were in agreement with the 
published data, which provided evidence of good 
reproducibility of the method. GD2 ganglioside anal-
ysis by HPLC has not been published previously, so 
the value of 2.48 GU obtained for the GD2 retention 
time cannot be compared with any available studies 
(Table 1).
Quantitative analysis of hPlc data. On the 
basis of quantitative analysis of samples containing 
standards of known ganglioside content, a relation-
ship between fluorescence signal and the amount of 
ganglioside was established. For GD2 ganglioside, 
a peak area of 1 000 000 corresponded to 16 pmol. 
For GD3 ganglioside, a peak area of 1 000 000 cor-
responded to 1.25 nmol. Those values were used to 
convert the fluorescence signal to the ganglioside 
concentration in the plasma samples.
GD2 ganglioside analysis by flow cytom-
etry. For additional confirmation of the quantitative 
HPLC analysis, flow cytometry was used as a ref-
erence method, as it allows quantitative assessment 
of antigen expression. One hundred thousand cells 
of five selected human cell lines (IMR-32, HTLA-
230, BE(2)-C, SH-SY5Y — neuroblastoma, SK-MEL-
28 — melanoma) were suspended in phosphate-
buffered saline (PBS) with 10% foetal bovine serum 
(FBS) and centrifuged at 800 × g. Subsequently, the 
cells were suspended in a solution of 14G2a murine 
monoclonal antibody at a concentration of 1 μg/ml 
in PBS with 10% FBS. After a 45-min incubation on 
ice, samples were centrifuged again and washed 
twice with cold PBS with 10% FBS. 14G2a antibod-
ies bound to cell surface were detected using (Fab’)2 
antibody fragments coupled with fluorescein isothio-
cyanate (ICN, Cat. No. 55526). Secondary antibodies 
used were diluted 1:40 in PBS with 10% FBS for 45 
min on ice. After washing the cells were suspended 
in PBS with 10% FBS and analysed with a FACScan 
cytometer (BD Biosciences) equipped with Cellquest 
software. The level of GD2 ganglioside expression 
was presented as the fluorescence index, according 
to the formula:
[fluorescence index] = ([% positive cells] × MFI)/100%
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where MFI is mean fluorescence intensity of the 
sample. The values obtained for the five cell lines 
were then compared with the result of HPLC analy-
sis performed on samples of the same cells.
statistical analysis: Arithmetic mean was the 
estimator of the expected value. Student’s t-test was 
used to compare the average values: P-value of 0.05 
was the significance level cut-off, and for P-values 
in the range of 0.05–0.10 the results were interpreted 
as a trend indication. Correlation between data sets 
was assessed using the squared Pearson’s correla-
tion coefficient. The Excel spreadsheet, a part of Mi-
crosoft Office 2003 package, was used for statistical 
analysis.
resulTs
Quantitative analysis of GD2 ganglioside
HPLC analysis was performed for all sam-
ples from the NB patients, as well as control non-
NB samples. The concentration of GD2 ganglioside 
in serum samples of patients with NB ranged from 
0 to 3 940 pmol/ml, with an average value of 660.7 
pmol/ml for all 42 samples analysed. The mean con-
centration for samples collected prior to treatment 
was 591.4 pmol/ml (31 samples), for those collected 
after treatment — 1 156.1 pmol/ml (7 samples), and 
for follow-up samples — 330.3 pmol/ml (4 samples). 
The average GD2 content in serum of non-NB pa-
tients was 106.1 pmol/ml (7 samples). The results 
indicate a substantial difference in GD concentra-
tions between serum samples from NB patients and 
age-matched non-NB patients. The concentration of 
GD2 in NB samples was on average 6.2 times higher 
than in non-NB samples (660.7 pmol/ml versus 106.1 
pmol/ml), but the difference was not statistically sig-
nificant.
correlations with known prognostic factors and 
other parameters
The analysis also showed that among the 31 
patients from whom serum samples were collected 
before treatment, 14 (45.2%) had elevated GD2 con-
centrations in plasma as compared to non-NB sam-
ples (over 106.1 pmol/ml), and the average value for 
this group was 1 239 pmol/ml. Nevertheless, statis-
tical analysis failed to reveal any direct correlations 
with known prognostic factors. In patients with fa-
vourable tumour histology, the average level of GD2 
in plasma was 623.1 pmol/ml, while in the group 
with unfavourable histology — 511.0 pmol/ml. The 
mean value for patients younger than 1 year was 
360.3 pmol/ml, while for patients older than 1 year 
— 718.6 pmol/ml. In patients with MYCN oncogene 
amplification in the tumour, GD2 concentration in 
plasma was 24.1 pmol/ml on average, while it was 
729.5 pmol/ml for cases with no MYCN amplifica-
tion. The differences between the compared groups 
were not statistically significant. The concentration 
of GD2 in the plasma of patients before treatment 
was 595.7 pmol/ml for patients with NB stages 1–3, 
while for patients in stage 4 (excluding 4S) it was 
564.2 pmol/ml. There were no statistically significant 
differences between these groups. The average result 
for patients in stages 1–4 (excluding 4S) was 591.4 
pmol/ml. The average content of GD2 ganglioside 
according to sex of patients was as follows: female 
— 707.9 pmol/ml, male — 467.2 pmol/ml. Also that 
difference was not statistically significant.
changes of GD2 level during treatment
Analysis of chromatograms obtained for dif-
ferent samples from the same patient allowed track-
ing of changes in GD2 concentrations in the course 
of treatment (Fig. 2). The GD2 concentration in the 
plasma decreased substantially during treatment. 
Table 1. comparison between qualitative results produced with the method described in this work and results pub-
lished by Wing et al., 2001.
Retention time was expressed in glucose units (GU); by definition, retention time equals 2.00 GU for arabinobiose and 
3.00 GU for arabinotriose.
Standard sample Retention timepublished by Wing et al., 2001 [GU]
Retention time
measured with the described method [GU]
GM1 1.91 2.01
Arabinobiose 2.00 2.00
GM3 2.04 2.11
GD1b 2.34 2.28
GD3 3.00 2.78
Arabinotriose 3.00 3.00
GD1a 3.26 3.14
GT1b 3.73 3.73
GD2 not measured 2.48
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Figure 2. GD2 level in serum samples of four patients for whom both pre-treatment and post-treatment samples were 
available.
The following changes in GD2 level were detected throughout therapy: 29% decrease for patient A, 16% decrease fol-
lowed by diminishing to undetectable level for patient B, 71% decrease for patient C and 88% decrease for patient D; 
panel E, reference samples (GD2 standard, non-NB sample, blank sample).
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The average GD2 level after treatment — calculat-
ed for the four patients from whom relevant sam-
ples were available — was 30% of the pre-treatment 
level. This may provide additional evidence that the 
level of GD2 ganglioside is correlated with the oc-
currence of active disease and the treatment leads to 
its decrease.
Analysis of gangliosides other than GD2
The method of glycolipid analysis with HPLC 
can be extended to other ganglioside species present 
in human plasma. With the use of appropriate stand-
ards, the analysis can be performed simultaneously 
for many types of gangliosides in the same plasma 
sample. In this work, GD3 ganglioside analysis was 
chosen for comparison with the GD2 concentration 
studies. The chemical structure of GD3 is similar 
to that of GD2, but GD3, unlike GD2, is present in 
normal blood plasma. The concentration of GD3 
ganglioside was evaluated in all samples analysed 
for the content of GD2. The level of GD3 was ap-
proximately two magnitudes of order higher than 
the GD2 concentration. In plasma samples of NB 
patients GD3 concentration varied from 0 to 107.3 
nmol/ml, with an average value of 21.8 nmol/ml for 
all 42 samples analysed. The average level of GD3 in 
non-NB plasma samples was similar — 22.7 nmol/ml 
(7 samples). A comparison between average concen-
trations of GD2 and GD3 in NB and non-NB plasma 
samples is shown in Fig. 3. In 26 serum samples 
from NB patients the GD3 concentration was below 
the average for all NB samples (21.8 nmol/ml), while 
in 16 samples the GD3 level exceed this value. Dur-
ing treatment (as followed in 4 patients) the level 
of GD3 decreased in three cases by 79–91%, and in-
creased by about 74% in one case. There was no re-
lation between the content of GD3 ganglioside and 
clinical factors such as sex, age, stage of disease or 
the outcome of treatment. The GD3 level showed no 
correlation with the level of GD2 measured in the 
same samples (Fig. 4).
comparison between hPlc analysis and flow cy-
tometry results
To confirm the quantitative nature of the 
chromatographic method, results of GD2 ganglioside 
analysis were compared with GD2 expression level 
estimated with a reference method of flow cytom-
Figure 3. GD2 and GD3 ganglioside concentration in plasma samples.
Mean ganglioside concentration in plasma samples for GD2 (left) and GD3 (right) ganglioside; NB — patients with neu-
roblastoma, non-NB — other paediatric patients. The concentration of GD2 ganglioside in NB samples (n = 42) ranged 
from 0 to 3 940 pmol/ml with a mean value of 660.7 pmol/ml. The average GD2 content in serum of 7 non-NB patients 
was 106.1 pmol/ml.
Figure 4. correlation between GD2 and GD3 concentra-
tion in nB plasma samples.
The squared Pearson’s correlation coefficient equals 
0.1052.
Table 2. GD2 ganglioside analysis performed with hPlc 
and flow cytometry in five different cell lines.
HPLC results are expressed as fluorescence peak areas. 
Flow cytometry results are shown as fluorescence index. 
For flow cytometry, cells were stained with anti-GD2 
murine monoclonal antibody and FITC-conjugated anti-
mouse secondary antibodies. Cell lines: IMR-32, HTLA-
230, BE(2)-C, SH-SY5Y — neuroblastoma; SK-MEL-28 
— melanoma.
Cell line HPLC signal Flow cytometry
IMR-32 480 129 431.5
HTLA–230 574 594 425.8
BE(2)-C 316 726 345.2
SH-SY5Y 368 343 339.1
SK-MEL-28 0    4.2
Correlation coefficient R2 = 0.9277
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etry, which is commonly used in antigen expression 
studies. Five different human cell lines were ana-
lysed simultaneously with both methods (Table 2). 
The results of the comparison suggest that HPLC 
analysis is a sensitive and quantitative method for 
GD2 ganglioside analysis.
DIscussIOn
The HPLC method developed for the pur-
pose of this study can be used to detect ganglio-
sides in plasma samples at the picomole level with 
the sample volume of less than 50 μl. It should be 
noted that the previously described methods based 
on thin-layer chromatography require approximate-
ly 1 ml of plasma (Ladisch & Gillard, 1987). In the 
case of small children the amount of blood that can 
be collected is limited. In addition, the novel HPLC 
method has a number of advantages, discussed be-
low.
The results of GD2 concentration analysis are 
consistent with previously published data (Ladisch 
et al., 1987). Although no correlations between clini-
cal data and the concentration of GD2 in the plasma 
of patients were found, it cannot be excluded that a 
longer period of observation following the therapy 
could lead to more definite conclusions. The search 
for new methods of prognosis is particularly impor-
tant in the case of NB due to the minimal residual 
disease, which outlasts the treatment of advanced 
forms of this cancer and often leads to relapse.
The measured level of GD2 ganglioside is 
characterised by high variability among individual 
patients. Similar observations have already been 
published (Valentino et al., 1990), but more recent 
works suggest that the phenomenon of ganglioside 
shedding may be highly complex (e.g. Kong et al., 
1998). The universal expression of GD2 ganglioside 
in NB tumours is a paradigm in NB biology (Wu et 
al., 1986). However, it is not clear whether this as-
sumption is fully justified. The level of GD2 expres-
sion in NB cells in vitro is varied (Chen et al., 2000); 
moreover, there have been reports of NB tumours 
that completely lack GD2 expression (Schumacher-
Kuckelkorn et al., 2005) — a fact that can have sig-
nificant clinical implications. It should be noted, 
however, that those publications have been much 
criticised by researchers in the field of NB diagnosis 
and therapy.
This HPLC method allows simultaneous 
analysis of a number of different species of plasma 
gangliosides. Potentially, it is possible to analyse se-
rum samples from patients with other diseases. Gan-
glioside expression is altered in melanoma cells, in 
which the level of GM2, GD2 and GD3 gangliosides 
can be elevated (Hakomori, 2001). Other examples 
are: small cell lung cancer, astrocytoma, soft tissue 
sarcoma. Analysis of plasma gangliosides may be 
useful in prognosis of the disease (Perez et al., 2002). 
Extension of the analysis to other ganglioside spe-
cies requires as little as an appropriate qualitative 
and quantitative standardisation by using high pu-
rity ganglioside preparations.
Simultaneous analysis of different ganglio-
sides may have an additional aspect related to the 
biosynthesis pathway of b-series gangliosides: GD3 
→ GD2 → GD1b → GT1b → GQ1b. NB cell lines ex-
hibit low expression of complex gangliosides (GD1b, 
GT1b, GQ1b) of this pathway (Hettmer et al., 2005). 
It seems that differences in the expression profile 
of b-series gangliosides may have a stronger clini-
cal relevance than has the level of GD2 ganglioside 
alone (Hettmer et al., 2003). Under the influence of 
13-cis-retinoic acid in vitro, NB cells change the gan-
glioside expression pattern towards more complex 
structures (Hettmer et al., 2004). 13-cis-retinoic acid 
is already used in the treatment of patients with NB, 
and a study of changes in the ganglioside synthe-
sis during treatment is possible using the proposed 
analytical method, although it would require stand-
ardisation.
Reports published in recent years suggest that 
it is possible to further improve the sensitivity of 
the assay by using an alternative method of glycan 
labelling using 2-aminobenzoic acid and several fur-
ther modifications (Neville et al., 2004).
HPLC may also be useful for the analysis of 
other components of the ganglioside biosynthesis 
pathway, such as ceramide and sphingosine (He 
et al., 2005). Studies confirm that high-performance 
liquid chromatography potentially has powerful ap-
plications in clinical practice, which offers hope for 
gradual improvement in diagnosis and prognosis 
of cancer on the basis of well-defined, measurable 
factors, in accordance with the concept of evidence-
based medicine.
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